Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: A case report

Abstract

Background: Novel therapeutic agents are currently being investigated for neuroendocrine tumour treatment. Case presentation. We report here on the case of a patient presenting with hypersensitivity pneumonitis while being treated with everolimus, a mammalian target of rapamycin (mTOR) inhibitor. Conclusion: Side effects of everolimus should be familiar to clinicians, including nonspecialists, and be monitored carefully to allow for prompt management. © 2013 Sibertin-Blanc et al.; licensee BioMed Central Ltd.